<DOC>
	<DOCNO>NCT02069080</DOCNO>
	<brief_summary>In mouse model patient , expression chemokine receptor CXCR4 various cancer correlate aggressive biological behavior , include increase rate certain site metastasis , decrease survival . Plerixafor ( Mozobil ; Genzyme ; Cambridge , MA ) identify specific inhibitor CXCR4 , currently approve Food Drug Administration stem-cell mobilize agent combination granulocyte colony-stimulating factor treatment non-Hodgkin 's lymphoma multiple myeloma . Our group recently show plerixafor label positron-emitting radionuclide copper-64 ( ( 64 ) Cu ) form ( 64 ) Cu-plerixafor , use visualize CXCR4-positive tumor xenograft mice use small-animal positron emission tomography ( PET ) . Determining CXCR4 expression tumor use ( 64 ) Cu-plerixafor PET/computerized tomography ( CT ) scanning could useful predict tumor behavior response current experimental therapy , include therapy target CXCR4 , could lead effective personalized cancer treatment . This study primary objective evaluate ( 64 ) Cu-plerixafor image agent quantify CXCR4 expression subject ( great equal 18 year age ) cancer ; least 1 detectable solid tumor great equal 2 cm diameter find outside lymph node , bone marrow , liver , gallbladder , kidney , bladder , brain ; preexist biopsy tumor obtain since first detection current occurrence/recurrence disease . The secondary objective correlate ( 64 ) Cu-plerixafor standardize uptake value target lesion level CXCR4 expression detect via immunohistochemistry calculate human dosimetry ( 64 ) Cu-plerixafor . Preexisting tumor biopsy less equal 75 subject recruit National Cancer Institute Georgetown University Hospital evaluate CXCR4 expression via immunohistochemistry . Subjects meet eligibility criterion continue onto study . Five subject CXCR4-positive tumor biopsy administer initial intravenous infusion ( 64 ) Cu-plerixafor ( 8 +/-0.8 mCi ; 0.48+/- 0.048 rem ; exceed 5 microg ( 64 ) Cu -plerixafor ) 2 minute . They undergo initial low-dose transmission CT scan follow 3 consecutive torso PET scan soon practical infusion , 2 additional PET/CT scan 4 hour +/- 1 hour 24 hour +/- 2 hour post-infusion . Human dosimetry calculate base result , maximum dose use , exceed calculate limit total effective dose 5 rem , radiation exposure limit organ . The remain subject CXCR4-positive ( n=15 ) CXCR4-negative ( n=5 ) tumor biopsy administer 64Cu-plerixafor , newly calculate dose , undergo 1 PET/CT scan 1 4 hour post-infusion , depend dosimetry result . All subject undergo one comprehensive final study visit study day 19 23 ( 11-17 day injection ( 64 ) Cu -plerixafor ) . Additionally , blood collect 2 time study day 13-16 study day 26-30 measure blood cell count .</brief_summary>
	<brief_title>Imaging CXCR4 Expression Subjects With Cancer Using 64 Cu-Plerixafor</brief_title>
	<detailed_description>In mouse model patient , expression chemokine receptor CXCR4 various cancer correlate aggressive biological behavior , include increase rate certain site metastasis , decrease survival . Plerixafor ( Mozobil ; Genzyme ; Cambridge , MA ) identify specific inhibitor CXCR4 , currently approve Food Drug Administration stem-cell mobilize agent combination granulocyte colony-stimulating factor treatment non-Hodgkin 's lymphoma multiple myeloma . Our group recently show plerixafor label positron-emitting radionuclide copper-64 ( 64Cu ) form 64Cu-plerixafor , used visualize CXCR4-positive tumor xenograft mice use small-animal positron emission tomography ( PET ) . Determining CXCR4 expression tumor use 64Cu-plerixafor PET/computerized tomography ( CT ) scanning could useful predict tumor behavior response current experimental therapy , include therapy target CXCR4 , could lead effective personalized cancer treatment . This study primary objective evaluate 64Cu-plerixafor imaging agent quantify CXCR4 expression subject ( great equal 18 year age ) cancer ; least 1 detectable solid tumor great equal 1.5 cm diameter find outside vertebral body , liver , gallbladder , kidney , bladder ; tissue sample ( ) tumor obtain since first detection current occurrence/recurrence disease . The secondary objective correlate 64Cu-plerixafor standardized uptake value target lesion level CXCR4 expression detect via immunohistochemistry calculate human dosimetry 64Cu-plerixafor . Tumor sample less equal to75 subject recruit National Cancer Institute Georgetown University Hospital evaluate CXCR4 expression via immunohistochemistry . With exception subject adrenocortical carcinoma , evaluation tissue expression CXCR4 require PET scan . Subjects meet eligibility criterion continue onto study . Five subject adrenocortical carcinoma and/or CXCR4-positive tumor sample administer initial intravenous infusion 64Cu-plerixafor ( 8+0.8 mCi ; 0.48+0.048 rem ; exceed 5 g 64Cu-plerixafor ) Day 0 . They undergo initial low-dose transmission CT scan follow 3 consecutive torso PET scan soon practical infusion , 2 additional PET/CT scan 4 hour +/- 1 hour 24 hour +/- 3 hour post-infusion . Human dosimetry calculate base result , dose may adjust , exceed calculate limit total effective dose 5 rem , radiation exposure limit organ . The remain subject administer 64Cu-plerixafor , newly calculate dose , undergo 1 PET/CT scan 1 4 hour post-infusion , depend dosimetry result . All subject undergo assessment NIH phone study Day 14 3 . Additionally , blood collect 3 time Day 7 2 , Day 14 3 Day 21 3 measure blood cell count , urine collect Day 7 2 .</detailed_description>
	<mesh_term>JM 3100</mesh_term>
	<criteria>INCLUSION CRITERIA : Screening Phase Subjects ( great equal to18 year age ) cancer ; least 1 detectable solid tumor great equal 1.5 cm diameter find outside vertebral body , liver , gallbladder , kidney , bladder ; , exception adrenocortical carcinoma , preexist tumor sample ( ) cancer obtain since first detection current occurrence/recurrence disease eligible participate screen portion study . Study Phase Subjects reproductive potential eligible enter study agree use 2 form contraception 3 week prior study start 1 month administration 64Cuplerixafor , : Hormonal contraception . Male female condom without spermicide . Diaphragm cervical cap spermicide . Intrauterine device . Male subject may commence contraception begin time infusion 64Cuplerixafor . EXCLUSION CRITERIA : Screening Phase Subjects know meet Study Phase exclusion criterion screen period may exclude enter Study Phase . Study Phase Individuals meet follow criterion eligible participate study : 1 . Karnofsky Performance Scale Index ( KPSI ) &lt; 70 . 2 . Women pregnant lactating . 3 . History lifethreatening cardiac arrhythmia . 4 . Absolute neutrophil count &lt; 1000/microliters . 5 . Platelet count &lt; 100,000/microliters . 6 . Alanine transaminase , aspartate aminotransferase , alkaline phosphatase , bilirubin level great equal 4 time upper limit normal , calculated creatinine clearance rate le equal 50 mL/min . 7 . Treatment plerixafor imaging agent radioisotope label molecule administer &lt; 10 halflives prior administration 64Cuplerixafor . 8 . Research radiation exposure past 12 month , add radiation exposure study , exceed 5 rem . 9 . Allergy plerixafor . 10 . Severe claustrophobia unresponsive anxiolytic . 11 . Weight 325 pound . 12 . History illness condition , investigator opinion , may substantially increase risk associate subject participation study , may compromise scientific objective . CoEnrollment Guidelines Coenrollment trial involve infusion radioactive isotopes/molecules research purpose plerixafor prohibit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 13, 2016</verification_date>
	<keyword>Positron Emission Tomograhy</keyword>
	<keyword>Metastasis</keyword>
</DOC>